ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin that activates tissue-protective signaling without stimulating red blood cell production, and is under clinical investigation primarily for small fiber neuropathy and inflammatory conditions.
What it does
ARA-290 is engineered from the B helix of erythropoietin (EPO), the hormone that drives red blood cell production. The key insight behind it is that EPO has two separate receptor systems. The classical homodimer (two identical EPO receptors paired together) handles red blood cell production. A second receptor complex — the innate repair receptor (IRR), a pairing of the EPO receptor with the beta common receptor (βcR) — handles tissue protection and repair. ARA-290 binds only the IRR PubMed 38943972, which means you get the protective effects of EPO without the dangerous side effect of polycythemia (an excess of red blood cells that thickens the blood and raises clotting risk).
Once bound to the IRR, ARA-290 triggers two well-characterized signaling pathways: JAK2/STAT3 (a cascade that regulates cell survival and inflammation) and PI3K/AKT (a pathway involved in cell growth and protection against programmed cell death). The downstream result is suppression of NF-κB — a master switch for inflammation — which reduces the production of pro-inflammatory signaling proteins including TNF-α, IL-1β, and IL-6 PubMed 29880388. ARA-290 also shifts macrophage behavior toward the M2 phenotype, meaning the macrophages favor tissue repair over tissue destruction PubMed 34343617.
The IRR is expressed on neurons, Schwann cells (the cells that wrap and maintain peripheral nerve fibers), endothelial cells lining blood vessels, and immune cells PubMed 38943972. This distribution explains ARA-290's range of investigated applications: peripheral nerve repair, ischemic tissue protection, kidney protection, and islet cell (insulin-producing pancreatic cell) preservation PubMed 34498509, PubMed 32345869.
What the evidence shows
Small fiber neuropathy Two Phase II human trials; moderate sample sizes; strongest clinical evidence base for this peptide
Small fiber neuropathy is damage to the thin, unmyelinated nerve fibers that carry pain and temperature signals. ARA-290 was tested in sarcoidosis patients who had developed this condition, a group where nerve damage is well-documented and measurable via corneal confocal microscopy — a non-invasive technique that images small nerve fibers in the eye as a proxy for systemic nerve health. A Phase II trial NCT02039687 found that ARA-290 improved both subjective neuropathic symptoms and corneal nerve fiber density compared to placebo. A separate analysis confirmed that corneal nerve fiber measurements add meaningful diagnostic and treatment-response data in this population Michael 2018.
A parallel trial in prediabetes and type 2 diabetes NCT01933529 investigated whether ARA-290 could slow or reverse diabetic small fiber neuropathy, which affects a large proportion of people with long-standing diabetes S 2021. EPO-derived peptides have shown clear mechanistic support for peripheral nerve protection in animal models, including Schwann cell survival and axonal regeneration promotion PubMed 38943972. The human trial results were consistent with that mechanism, though the field still needs larger, longer trials to establish durable benefit.
Diabetic macular edema One Phase II human trial; limited sample size
Diabetic macular edema is fluid accumulation in the central retina caused by leaky, damaged blood vessels — a leading cause of vision loss in diabetes. A Phase 2 trial found that cibinetide did not meet its primary endpoint for visual acuity improvement PubMed 32674280, though supportive preclinical work showed that cibinetide enhances the vasoreparative potential of endothelial colony-forming cells (the cells that repair damaged vessel walls) in ischemic retinal tissue PubMed 30876881. A follow-up trial is registered NCT06626971, suggesting investigators see enough signal to continue. Current evidence does not support efficacy for this indication.
Kidney protection Solid rodent evidence; no completed human trials
Multiple animal studies show ARA-290 reduces kidney damage from chemotherapy toxicity (cisplatin) PubMed 36085231, high-glucose injury to tubular cells PubMed 34134477, and renal transplant injury via NF-κB suppression PubMed 29880388. In a hemolytic-uremic syndrome mouse model, targeting the IRR axis attenuated kidney damage PubMed 36211426. These results are mechanistically coherent but have not been tested in human renal disease trials.
Islet transplantation / diabetes Preclinical and early translational; one small human islet study
Pancreatic islets — the cell clusters that produce insulin — are extremely fragile during and after transplantation. Cibinetide improved isolated human islet survival under stress conditions in vitro and improved engraftment outcomes in a preclinical transplant model PubMed 34498509, PubMed 32345869. These findings are relevant to type 1 diabetes treatment but are far from clinical application.
Cardiac and cerebral ischemia protection Rodent evidence only
In mouse models of cerebral ischemic stroke, ARA-290 reduced brain tissue injury through βcR-dependent signaling PubMed 38488446. A separate rodent study found that an EPO-derived non-hematopoietic peptide reduced cardiac inflammation and attenuated age-related declines in heart function PubMed 36741836. A radiolabeled version of ARA-290 has been synthesized and evaluated as an imaging tracer for cardiac ischemic regions PubMed 35317117, suggesting interest in both therapeutic and diagnostic applications. No human ischemia trials are registered.
Neuroprotection in traumatic brain injury Preclinical only; active mechanistic research
Recent reviews identify EPO derivatives including ARA-290 as candidates for traumatic brain injury given their ability to reduce neuroinflammation and support neuronal survival PubMed 41659975. Animal data on cognitive outcomes are emerging — one db/db mouse study linked immunometabolic dysregulation to executive cognitive dysfunction in a context where IRR-targeting may be relevant PubMed 41933665. This remains an early-stage research area.
Bone density In vitro and mouse data only
ARA-290 inhibited osteoclastogenesis (the formation of bone-resorbing cells) in vitro and increased bone mineral density in mice PubMed 35008482. The mechanism is plausible given IRR expression on bone marrow immune cells, but no human data exist.
How it's used
In clinical trials, ARA-290 has been administered subcutaneously (injected under the skin) at doses ranging from 2 mg to 4 mg daily NCT02039687, NCT01933529. The plasma half-life is approximately 2 minutes, which is short, but receptor binding duration is substantially longer — a pattern seen with other peptides where rapid clearance does not predict short biological effect. Self-reported protocols outside trials have explored the same 2–4 mg daily subcutaneous range, typically dosed in the morning. An 8 mg daily dose has been referenced in dose-ranging contexts but is less commonly reported. No oral form has been validated in trials.
Side effects and safety
In Phase II trials, ARA-290 was generally well tolerated. The most commonly reported adverse effects were injection site reactions and mild headache. Moderate effects including dizziness, fatigue, and nausea were documented but not frequent enough to drive discontinuation in reported trials PubMed 32674280, NCT02039687. Critically, no erythropoietic effects (elevated red blood cell counts or hemoglobin) have been observed, which was the primary safety concern motivating ARA-290's development over EPO itself PubMed 38943972. No severe adverse events have been attributed to ARA-290 in published data. Long-term safety data beyond short trial windows do not exist. Theoretical concerns about use in active malignancy arise because IRR signaling promotes cell survival — the same mechanism that makes it neuroprotective could theoretically support tumor cell survival, though this has not been demonstrated. Data in pregnancy are absent; use is contraindicated.
Bottom line
ARA-290 has the most credible evidence base among EPO-derived peptides for treating small fiber neuropathy, with Phase II trial data showing nerve fiber regeneration and symptom improvement in sarcoidosis patients — a meaningful signal, though not yet from large confirmatory trials. For most other investigated applications, the evidence is preclinical and requires human validation before drawing practical conclusions. People researching it for neuropathic conditions have a mechanistically grounded and clinically tested rationale; those looking to it for off-label purposes outside neuropathy are working largely from animal data.